4D Molecular Therapeutics’ (FDMT) “Sell (D-)” Rating Reaffirmed at Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating reissued by stock analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

A number of other research firms also recently commented on FDMT. BMO Capital Markets downgraded 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $40.00 to $15.00 in a report on Monday, January 13th. Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. Morgan Stanley reduced their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a report on Monday, January 13th. Bank of America dropped their target price on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, Royal Bank of Canada dropped their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.56.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock traded down $0.10 during trading on Friday, hitting $4.58. The company’s stock had a trading volume of 927,608 shares, compared to its average volume of 992,118. 4D Molecular Therapeutics has a 1-year low of $4.50 and a 1-year high of $36.25. The stock’s fifty day moving average is $6.66 and its 200 day moving average is $11.49. The stock has a market capitalization of $211.73 million, a price-to-earnings ratio of -1.61 and a beta of 2.81.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several large investors have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of 4D Molecular Therapeutics during the third quarter worth approximately $40,000. Values First Advisors Inc. acquired a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. boosted its stake in 4D Molecular Therapeutics by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after purchasing an additional 3,922 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in 4D Molecular Therapeutics during the third quarter worth about $108,000. Finally, Hsbc Holdings PLC acquired a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $246,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.